Compare RDY & HMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | HMY |
|---|---|---|
| Founded | 1984 | 1950 |
| Country | India | South Africa |
| Employees | N/A | 34350 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.7B |
| IPO Year | 2001 | N/A |
| Metric | RDY | HMY |
|---|---|---|
| Price | $13.34 | $16.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.90 | $16.00 |
| AVG Volume (30 Days) | 2.2M | ★ 5.0M |
| Earning Date | 05-08-2026 | 02-04-2016 |
| Dividend Yield | 0.54% | ★ 1.00% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.81 | $37.77 |
| Revenue Next Year | $3.20 | $28.06 |
| P/E Ratio | $18.67 | ★ $15.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.82 | $13.03 |
| 52 Week High | $16.17 | $26.04 |
| Indicator | RDY | HMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 50.35 |
| Support Level | $13.32 | $16.06 |
| Resistance Level | $14.14 | $21.83 |
| Average True Range (ATR) | 0.23 | 0.70 |
| MACD | -0.04 | 0.46 |
| Stochastic Oscillator | 43.86 | 71.56 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.